Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Caroline S Bennette"'
Autor:
Cliff C Kerr, Robyn M Stuart, Dina Mistry, Romesh G Abeysuriya, Katherine Rosenfeld, Gregory R Hart, Rafael C Núñez, Jamie A Cohen, Prashanth Selvaraj, Brittany Hagedorn, Lauren George, Michał Jastrzębski, Amanda S Izzo, Greer Fowler, Anna Palmer, Dominic Delport, Nick Scott, Sherrie L Kelly, Caroline S Bennette, Bradley G Wagner, Stewart T Chang, Assaf P Oron, Edward A Wenger, Jasmina Panovska-Griffiths, Michael Famulare, Daniel J Klein
Publikováno v:
PLoS Computational Biology, Vol 17, Iss 7, p e1009149 (2021)
The COVID-19 pandemic has created an urgent need for models that can project epidemic trends, explore intervention scenarios, and estimate resource needs. Here we describe the methodology of Covasim (COVID-19 Agent-based Simulator), an open-source mo
Externí odkaz:
https://doaj.org/article/578afb778b5440bd928c428097f61882
Autor:
Josh J. Carlson, David D. Kim, Gregory F. Guzauskas, Caroline S. Bennette, David L. Veenstra, Anirban Basu, Nathaniel Hendrix, Dawn L. Hershman, Laurence Baker, Scott D. Ramsey
Publikováno v:
Cancer Medicine, Vol 7, Iss 9, Pp 4251-4260 (2018)
Abstract Background The Institute of Medicine has called for approaches to help maximize the return on investments (ROI) in cancer clinical trials. Value of Research (VOR) is a health economics technique that estimates ROI and can inform research pri
Externí odkaz:
https://doaj.org/article/01b3a7f2a75d436c9b5e1380b6435246
Publikováno v:
JNCI Cancer Spectrum. 6
Background African American men have a higher burden of prostate cancer compared with other populations. We sought to determine if they experience disparities in access to prostate cancer clinical trials. Methods We created a database of all US count
Autor:
Caroline S. Bennette, David D. Kim, Anirban Basu, Josh J. Carlson, David L. Veenstra, Gregory F. Guzauskas, Scott D. Ramsey
Publikováno v:
PharmacoEconomics. 38:171-179
Value of information (VOI) analysis often requires modeling to characterize and propagate uncertainty. In collaboration with a cancer clinical trial group, we integrated a VOI approach to assessing trial proposals. This paper aims to explore the impa
Publikováno v:
Value in Health. 22:777-784
Background Innovations that extend life can generate option value and cost of experiencing future technologies. Objectives To understand how consideration of option value may affect the potential cost-effectiveness of a treatment through a case study
Publikováno v:
American Journal of Health Economics. 5:360-375
We estimated the average returns, in terms of patient survival, to the marginal innovations in the oral chemotherapy market induced by Part D expansion of oral chemotherapy coverage for elderly ind...
Publikováno v:
Health Economics. 28:855-867
A change in the expectations about future treatments may change the option value of a current treatment, thereby affecting its utilization. We conducted an interrupted time series analysis using a large administrative claims database to test whether
Autor:
Joshua S. Kraut, Ariel Bulua Bourla, Xinran Ma, Nathan C. Nussbaum, Kelly Magee, Bryan Bowser, Lawrence Bellomo, Meghna Samant, Olga Tymejczyk, Caroline S. Bennette, Melisa Tucker
Publikováno v:
Advances in Therapy
Introduction Effectiveness metrics for real-word research, analogous to clinical trial ones, are needed. This study aimed to develop a real-world response (rwR) variable applicable to solid tumors and to evaluate its clinical relevance and meaningful
Autor:
Edward A. Wenger, Assaf P. Oron, Michael Famulare, Prashanth Selvaraj, Bradley G. Wagner, Brittany Hagedorn, Sherrie L Kelly, Rafael C. Núñez, Robyn M. Stuart, Stewart T. Chang, Jamie A. Cohen, Gregory R. Hart, Amanda S Izzo, Romesh G. Abeysuriya, Michał Jastrzębski, Katherine Rosenfeld, Caroline S Bennette, Jasmina Panovska-Griffiths, Anna Palmer, Daniel J. Klein, Cliff C. Kerr, Dominic Delport, Nick Scott, Greer Fowler, Dina Mistry, Lauren George
Publikováno v:
Kerr, C C, Stuart, R M, Mistry, D, Abeysuriya, R G, Rosenfeld, K, Hart, G R, Núñez, R C, Cohen, J A, Selvaraj, P, Hagedorn, B, George, L, Jastrzȩbski, M, Izzo, A S, Fowler, G, Palmer, A, Delport, D, Scott, N, Kelly, S L, Bennette, C S, Wagner, B G, Chang, S T, Oron, A P, Wenger, E A, Panovska-Griffiths, J, Famulare, M & Klein, D J 2021, ' Covasim : An agent-based model of COVID-19 dynamics and interventions ', PLOS Computational Biology, vol. 17, no. 7, e1009149 . https://doi.org/10.1371/journal.pcbi.1009149
PLoS Computational Biology
PLoS Computational Biology, Vol 17, Iss 7, p e1009149 (2021)
PLoS Computational Biology
PLoS Computational Biology, Vol 17, Iss 7, p e1009149 (2021)
The COVID-19 pandemic has created an urgent need for models that can project epidemic trends, explore intervention scenarios, and estimate resource needs. Here we describe the methodology of Covasim (COVID-19 Agent-based Simulator), an open-source mo
Autor:
William M. Grady, Deborah A. Nickerson, Brian H. Shirts, Michael O. Dorschner, Bryan A. Comstock, Fuki M. Hisama, Xin Niu, Stephanie M. Fullerton, Ragan Hart, Peter Tarczy-Hornoch, Peggy D. Robertson, Wylie Burke, Robin L. Bennett, Donald L. Patrick, Martha Horike-Pyne, Laura M. Amendola, David L. Veenstra, Carlos J. Gallego, Gail P. Jarvik, Elisabeth A. Rosenthal, Caroline S. Bennette, Dean A. Regier, Susan Brown Trinidad, Chris Nefcy, Patrick J. Heagerty
Publikováno v:
Contemp Clin Trials
Background Clinical exome sequencing (CES) provides the advantage of assessing genetic variation across the human exome compared to a traditional stepwise diagnostic approach or multi-gene panels. Comparative effectiveness research methods offer an a